QSI vs DBVT vs ALKS vs PACB

For growth investors, Pacific Biosciences of California, Inc.

(PACB) is the stronger pick with 3. 9% revenue growth year-over-year, versus -20. 3% for Quantum-Si incorporated (QSI). Alkermes plc (ALKS) offers the better valuation at 24. 5x trailing P/E, making it the more compelling value choice. Analysts rate Quantum-Si incorporated (QSI) a "Buy" — based on 2 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Alkermes plc (ALKS) delivered a total return of +61.

7%, compared to -93. 9% for Pacific Biosciences of California, Inc. (PACB). Over 10 years, the gap is even starker: ALKS returned -12. 0% versus QSI's -90. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Alkermes plc (ALKS) is the lower-risk stock at 1.

00β versus Quantum-Si incorporated's 3. 69β — meaning QSI is approximately 270% more volatile than ALKS relative to the S&P 500. On balance sheet safety, Quantum-Si incorporated (QSI) carries a lower debt/equity ratio of 2% versus 142% for Pacific Biosciences of California, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Pacific Biosciences of California, Inc.

(PACB) is pulling ahead at 3. 9% versus -20. 3% for Quantum-Si incorporated (QSI). On earnings-per-share growth, the picture is similar: Quantum-Si incorporated grew EPS 28. 2% year-over-year, compared to -347. 5% for DBV Technologies S. A.. Over a 3-year CAGR, ALKS leads at 9. 9% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Alkermes plc (ALKS) is the more profitable company, earning 16.

4% net margin versus -41. 6% for Quantum-Si incorporated — meaning it keeps 16. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ALKS leads at 17. 2% versus -39. 8% for QSI. At the gross margin level — before operating expenses — ALKS leads at 86. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Alkermes plc (ALKS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1.

00)). Quantum-Si incorporated (QSI) carries a higher beta of 3. 69 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (ALKS: -12. 0%, QSI: -90. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.